Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 772–773 | Cite as

ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis

  • Joel M. Baumgartner
  • Razelle Kurzrock
ASO Author Reflections



Dr. Kurzrock has received research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant Health; consultant fees from Sequenom, Loxo and Actuate Therapeutics; and speaker fees from Roche. He also has an ownership interest in Curematch, Inc. Drs. Baumgartner has no relevant disclosures.


  1. 1.
    de Bree E, Koops W, Kroger R, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.CrossRefGoogle Scholar
  2. 2.
    Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.CrossRefGoogle Scholar
  3. 3.
    Schwaederle M, Chattopadhyay R, Kato S, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 2017;77(19):5419–27.CrossRefGoogle Scholar
  4. 4.
    Schwaederle M, Husain H, Fanta PT, et al. Use of liquid biopsies in clinical oncology: pilot experience in 168 patients. Clin Cancer Res. 2016;22(22):5497–505.CrossRefGoogle Scholar
  5. 5.
    Baumgartner JM, Raymond VM, Lanman RB, et al. Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann Surg Oncol. 2018;25(8):2400–8.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Surgical OncologyMoores Cancer Center, University of California San DiegoSan DiegoUSA
  2. 2.Center for Personalized Cancer TherapyUniversity of CaliforniaSan Diego, La JollaUSA

Personalised recommendations